Long-term Ultrasound-Enhanced Convective Injection Device for Neural Drug Delivery
Hou, J. F., Ornellas, S. B., Nowicki, M. O., Li, J., Leblanc, H., Tulu, B. S., Sadat, D., Mineo, M., Ramirez, S., Chiocca, H. A., Dagdeviren, C.†, “Long-term Ultrasound-enhanced Convective Injection Device for Neural Drug Delivery”, Device, 5, 101333, 2026.
Abstract
Delivering therapeutics to the brain faces two critical barriers: most drugs cannot cross the blood-brain barrier (BBB) due to their size at therapeutic concentrations and in situ injection methods require repeated invasive surgeries that risk damaging healthy tissue. Strategies to enhance drug delivery include transcranially disrupting the BBB with remote ultrasound (US), allowing systemically delivered drugs to transiently infiltrate the parenchyma, or injecting drugs locally under constant positive pressure using convection-enhanced delivery (CED). Systemic injection strategies are limited by off-target toxicity, and external US equipment is bulky and resource intensive. While CED enables targeted parenchymal distribution, it remains limited to acute applications with external equipment and poor tissue penetration due to resistance in densely packed neural tissue. Current approaches cannot provide chronic, controlled delivery of therapeutic payloads to the brain without repeated craniotomies and backflow loss. LUCID addresses these challenges by combining ultrasound-enhanced convective delivery with a fully implantable, wirelessly controlled platform that significantly enlarges parenchymal distribution volume relative to syringe-based CED. The platform demonstrates 20 h of continuous wireless operation in a tissue phantom, providing the technical foundation for future programmable, longitudinal therapeutic regimens that eliminate the need for repeated surgical access and expand distribution beyond what pressure-driven infusion alone can achieve.